Welcome to Dermbits! Watch short videos of KOLs answering your questions
Psoriasis
Who is the ideal patient for tapinarof, and are there any notable exclusions?
Featuring Tina Bhutani, MD, MAS
Psoriasis
What should patients expect when they stop treatment with tapinarof?
Featuring Tina Bhutani, MD, MAS
Psoriasis
What were the primary endpoints of the PSOARING 1 and PSOARING 2 trials for tapinarof?
Featuring Tina Bhutani, MD, MAS
Psoriasis
What is the role of the Aryl hydrocarbon receptor in psoriasis and psoriasis management?
Featuring Tina Bhutani, MD, MAS
Psoriasis
What are the latest advancements in understanding the pathogenesis of psoriasis?
Featuring Tina Bhutani, MD, MAS
Psoriasis
How do lifestyle factors like diet and stress impact your approach to psoriasis management?
Featuring Tina Bhutani, MD, MAS
Psoriasis
How do you counsel patients on quality of life impacts from psoriasis?
Featuring Tina Bhutani, MD, MAS
Vitiligo
How do you set expectations with patients before starting them on ruxolitinib for vitiligo?
Featuring Karan Lal, DO, MS, FAAD
Vitiligo
How quickly can patients expect to see results with ruxolitinib for vitiligo?
Featuring Karan Lal, DO, MS, FAAD
Vitiligo
Can ruxolitinib for vitiligo be used with other JAK inhibitors?
Featuring Karan Lal, DO, MS, FAAD
Vitiligo
What are the limitations of use for ruxolitinib for vitiligo?
Featuring Karan Lal, DO, MS, FAAD
Vitiligo
What follow-up or monitoring do you recommend for patients on ruxolitinib for vitiligo?
Featuring Karan Lal, DO, MS, FAAD
Vitiligo
How does your treatment approach differ in treating segmental vs nonsegmental vitiligo?
Featuring Karan Lal, DO, MS, FAAD
Vitiligo
How can dermatologists address challenges and disparities in access to vitiligo care?
Featuring Karan Lal, DO, MS, FAAD
Vitiligo
What is the mechanism of action for ruxolitinib for vitiligo?
Featuring Nicholas Brownstone, MD
Vitiligo
What are the most common adverse reactions seen with ruxolitinib for vitiligo?
Featuring Nicholas Brownstone, MD
24 of 513